Investor Relations

To Our Stakeholders

Performance was favorable in the Americas, EMEA* and other overseas regions, leading to substantially higher sales and income.

Achieved Double-Digit Sales Growth, Centered on Overseas Regions, Due in Part to the Impact of Yen Depreciation
Sharply Higher Income, Benefiting from Effects of Higher Sales and Yen Depreciation

During the first three months of the fiscal year ending March 31, 2015, Sysmex recorded a double-digit rise in net sales compared with the first three months of the preceding fiscal year, with sales growth centered on overseas regions. Income also rose substantially, due to the impact of higher sales, as well as yen depreciation. Net sales rose 18.2% year on year, with operating income up 83.3%, ordinary income up 68.2% and net income up 69.2%. At the exchange rates prevailing one year earlier, net sales would have been up 13.7% and operating income up 70.5%.

In Japan, sales increased in non-hematology fields* but declined in the hematology field*, causing a slight year-on-year decline in this region. All overseas geographic regions posted sales increases, with the Americas and EMEA generating particularly favorable results. In the Americas, sales surged 26.6% year on year, as healthcare system reform in the United States went into full-fledged motion—boosting sales of hematology instruments—and helped by robust sales in countries in Central and South America, including Peru, Mexico and Colombia. As a result, the Sysmex Group’s overseas sales ratio amounted to 83.8%.

We maintain unchanged the consolidated performance forecast we announced in May 2014 for the full fiscal year ending March 31, 2015. (Net sales of ¥210.0 billion, operating income of ¥36.0 billion, ordinary income of ¥36.0 billion and net income of ¥22.0 billion)

To meet expected global demand growth, Sysmex has established a new instrument factory, i-Square, and expanded existing factories at affiliated companies in Japan. By transitioning to a four-factory production structure in Japan, we have reinforced our capacity to manufacture in-vitro diagnostic instruments. As a result, going forward we expect to continue delivering high-quality, high-value-added products in a stable manner throughout the world.

* Europe, the Middle East and Africa
* Non-hematology field: in vitro diagnostics fields excluding hematology but including hemostasis, immunochemistry, urinalysis, clinical chemistry and others.
* Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.

Hisashi Ietsugu
Chairman and CEO


Related Links
 - Presentation
 - Financial Data
 - Financial Statement


President and CEO Hisashi Ietsugu
August 2014 
Hisashi Ietsugu
Chairman and CEO
Hisashi Ietsugu

Top of Investor Relation

Sysmex Corporation

Copyright© SYSMEX CORPORATION, All Rights Reserved.